5-Amino-1MQ Human Trials: What the Research Shows

Okay, real talk: 5-Amino-1MQ is the kind of compound where the internet is way ahead of the science. Scroll any biohacker forum and you will find people swapping notes on it like it is a settled thing — a tidy little metabolism molecule. The reality is messier and, honestly, more interesting. What actually exists is a small pile of animal and cell-model studies on an enzyme most people have never heard of, plus a wall of anecdotes. So the honest question is not whether 5-Amino-1MQ does something, but what has actually been measured, in what — mice, mostly — and where the research-grade material you can buy stops matching that story.^[1]

What it is, in plain English

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide — despite living in peptide-forum conversations. It is studied as an inhibitor of an enzyme called NNMT, short for nicotinamide N-methyltransferase. In plain terms: NNMT sits inside fat cells and other tissues and burns through a molecule the body also uses for cellular energy signaling. The whole idea researchers are chasing is simple to state — slow that enzyme down and see whether cellular energy balance shifts in a useful direction. That is the lever. Whether pulling it does anything meaningful in a human body is exactly what has not been established.^[2]

What it's commonly researched for

The headline interest is metabolism and body composition, with a side of NAD-related cellular energy pathways. That is the reason the biohacker crowd keeps bringing it up, and it is fair to front-load why people care. The caveat that has to travel with every one of those lines: this is research directed mainly at animal and cell models, it is not FDA-approved, and effects in humans are still being studied. Leading with the reason people are curious is honest; pretending the metabolism angle is settled science would not be.^{[1, 2]}

What researchers actually studied

The most-cited work is preclinical. In one line of research, knocking down NNMT activity in mice on a high-fat diet was associated with protection against diet-induced weight gain — a striking result that put the enzyme on the map as a metabolism target. A later study reported that a small-molecule NNMT inhibitor, given to mice, reduced diet-induced obesity measures. That is genuine, peer-reviewed signal, and it is why the interest is not pure hype. It is also, crucially, mouse and cell data: a specific model, specific endpoints, and no controlled human trial reading across to people. The mechanism is real; the leap to human outcomes is the part nobody has earned yet. The detail is worth having, because it is the part vendor pages skip. In the 2018 work, the inhibitors lowered intracellular 1-methylnicotinamide, raised intracellular NAD+ and S-adenosylmethionine, and suppressed lipogenesis in cultured adipocytes. In diet-induced obese mice, the authors reported lower body weight, less white adipose mass, smaller adipocytes and lower plasma total cholesterol, with no change in total food intake and no observable adverse effects over the study. The authors also reported that the methylquinolinium analogues did not inhibit related SAM-dependent methyltransferases or NAD+ salvage enzymes, which is the selectivity argument the whole target rests on. All of it is mouse and cell data.^{[1, 2]}

Human trials of 5-Amino-1MQ: what is registered

There are none. A ClinicalTrials.gov registry search for 5-Amino-1MQ returns zero registered studies, and searches for the broader terms "NNMT inhibitor" and "methylquinolinium" return zero as well. That is not a gap in reporting or a set of trials still reading out. No controlled human study of this compound has been registered at all. That matters more than it sounds. Registration happens at the start of a trial, not the end, so an empty registry means nothing is currently running and nothing has been formally started. Every number attached to this compound comes from mice, from cultured cells, or from someone on a forum. There is no human efficacy figure, no human safety window, and no human pharmacokinetic profile to report, because nobody has produced one. Anyone quoting a human result for 5-Amino-1MQ is either describing an animal study without saying so, or describing a clinic's own unpublished impressions. Neither is trial evidence.^[3]

What people report

In online communities, some people describe a shift in appetite or a bit more energy through the day. Others describe subtle changes they are not sure they can trust, and a few describe nothing at all — or mild stuff like nausea and headache that made them stop. A recurring, sensible theme in the better threads is people admitting they cannot separate the compound from diet changes they made at the same time. These are anecdotes, not evidence, and there is no way to know how representative any single story is. Listing the flat-nothing reports next to the enthusiastic ones is the whole point: both are real parts of what people actually say.^[3]

What the evidence does not show

The encouraging data lives almost entirely in animal and cell models. It does not establish that 5-Amino-1MQ changes body composition in people, it does not settle a human dose or safety window, and it says little about how the research-grade material sold for lab use behaves compared with what was studied. Reading a promising mouse result as a green light for humans is exactly the jump the evidence does not support. Early-stage and promising can be true at the same time as unproven — and here, all three are.^{[1, 3]}

Known and theoretical risks

Because no controlled human trials of 5-Amino-1MQ have been run or registered, the honest answer on side effects is that the full picture is not characterized. The considerations people raise — some reported, some theoretical — include nausea, headache and injection-site irritation with the injectable research form. Interfering with an enzyme tied to core cellular energy pathways is not a trivial thing to do long-term, and nobody has the human data to say what that looks like over time. On top of the compound itself, gray-market supply is its own hazard: research-grade material can carry contamination, endotoxins, or an identity that simply does not match the label, and none of that is visible in the vial.^[3]

Regulatory status

5-Amino-1MQ is not FDA-approved. It is sold for laboratory and research use only, not as a medicine or a supplement for human use. No controlled human trials of the compound are registered, so its effects in people are still being studied. There is no branded prescription version of it and no on-label human use to point to. Anyone framing it as a metabolism product ready for people is getting ahead of both the science and the regulatory reality.^[3]

References & sources

1. Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018;147:141-152.
2. Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 2014.
3. ClinicalTrials.gov (U.S. NIH) v2 API registry searches for "5-Amino-1MQ", "NNMT inhibitor" and "methylquinolinium", each returning totalCount 0 - no controlled human trials of the compound or its mechanism class are registered. Retrieved 2026-07-26.